Published in Eur J Cancer on January 01, 1992
Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res (2008) 2.94
Clinical relevance of single item quality of life indicators in cancer clinical trials. Br J Cancer (2001) 1.13
Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for clinical trials. Br J Cancer (1998) 0.97
Quality of life and understanding of disease status among cancer patients of different ethnic origin. Br J Cancer (2003) 0.88
Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG). Br J Cancer (1998) 0.83
A study of psycho-behavioral patterns in patients emerging from general anesthesia using sevoflurane, propofol and their combination in early, intermediate and late post-operative period: A randomized controlled trial. Anesth Essays Res (2015) 0.75
Evaluating Statistical Hypotheses Using Weakly-Identifiable Estimating Functions. Scand Stat Theory Appl (2013) 0.75
Standardisation of spirometry. Eur Respir J (2005) 48.20
Interpretative strategies for lung function tests. Eur Respir J (2005) 21.50
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol (2011) 13.95
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol (2013) 9.68
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol (2009) 9.18
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet (2007) 8.08
General considerations for lung function testing. Eur Respir J (2005) 7.99
Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J (2005) 7.58
Standardisation of the measurement of lung volumes. Eur Respir J (2005) 7.48
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol (2007) 7.33
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 6.02
Analysis of survival by tumor response. J Clin Oncol (1983) 5.91
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol (2005) 5.41
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol (2001) 5.31
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med (1991) 5.22
On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol (1983) 4.35
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol (2002) 4.32
Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med (1995) 4.03
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood (2001) 3.93
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet (2000) 3.79
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst (1998) 3.50
Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet (1999) 3.50
Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1996) 3.30
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol (2004) 3.29
Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood (2001) 3.24
Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol (1992) 3.17
Energy balance and colon cancer--beyond physical activity. Cancer Res (1997) 3.11
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer (1998) 3.03
Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet (2008) 2.91
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol (2006) 2.72
Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol (1989) 2.57
Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol (2001) 2.37
Adhesion of Streptococcus pneumoniae to human pharyngeal epithelial cells in vitro: differences in adhesive capacity among strains isolated from subjects with otitis media, septicemia, or meningitis or from healthy carriers. Infect Immun (1981) 2.33
Who gets chemotherapy for metastatic lung cancer? Chest (2000) 2.27
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol (2008) 2.26
A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med (2000) 2.17
A snapshot of waiting times for cancer surgery provided by surgeons affiliated with regional cancer centres in Ontario. CMAJ (2001) 2.11
Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol (2001) 2.05
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (2015) 2.05
Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. Ann Oncol (1998) 2.05
Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol (2002) 2.03
Outcome of pregnancy in survivors of Wilms' tumor. JAMA (1987) 2.00
Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group. J Clin Oncol (1992) 2.00
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol (1999) 1.98
A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. N Engl J Med (1994) 1.97
1st International consensus guidelines for advanced breast cancer (ABC 1). Breast (2012) 1.96
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol (2000) 1.92
Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol (2000) 1.91
Nasopharyngeal colonization during the first year of life. J Infect Dis (1992) 1.89
Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group. Ann Intern Med (1991) 1.88
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol (2007) 1.85
Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer (1997) 1.82
Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol (2000) 1.81
Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol (2000) 1.79
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol (2012) 1.79
Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet (2001) 1.79
Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol (1999) 1.77
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol (2003) 1.75
Meeting highlights: adjuvant therapy for primary breast cancer. J Natl Cancer Inst (1992) 1.70
A computerized diet history questionnaire for epidemiologic studies. J Am Diet Assoc (1994) 1.70
Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer. Ann Oncol (1996) 1.70
Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol (2007) 1.69
Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr (2001) 1.67
Outcome of special types of luminal breast cancer. Ann Oncol (2011) 1.67
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol (2008) 1.66
Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group. N Engl J Med (1994) 1.66
Cancer-testis antigen expression in triple-negative breast cancer. Ann Oncol (2010) 1.65
Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet (1994) 1.64
Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer (1993) 1.64
Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. International Breast Cancer Study Group. Int J Radiat Oncol Biol Phys (1996) 1.63